Clinical Trials

These are the trials that are currently open in the Early Phase Unit (Last updated July 2018).

Trial Short Name Molecular Target(s)   Patient Population Lead Investigator(s)
in Cambridge
 
 AZD1390 ATM with RT  Glioblastoma  S Jeffries / R Baird 
 AZD6738 combo
with olaparib
 ATR/PARP  Gastric cancer (low ATM expression) & BRCA
mutation/HRD high breast cancer
 D Jodrell
AZD8186   PIK3CB Prostate, TNBC, NSCLC, with pre-screening for
PTEN deficiency 
 R Baird
 BOS172722  Monopolar spindle 1
kinase inhibitor
Solid tumours suitable for weekly taxol  B Basu 
CALIBRATE cfDNA evaluation Patients on early phase clinical trials R Baird / S Pacey
 CamBMT1  EGFR/HER2 Operable brain metastasis (breast/lung)   R Baird
 CAM-PLEX   CXCR4  Metastatic pancreatic cancer with biopsiable disease    D Jodrell / B Basu 
 CURIS    PD-1/PD-L1/VISTA  Any tumour site with FDA approved immunotherapy option   S Pacey
 G1T38  CDK4/6 ER-positive breast cancer, CDK4/6 inhibitor plus fulvestrant  R Baird
 iBET Bromodomain  Haematologic malignancies  B Huntly 
 IMCgp100 201 Gp100 immunotoxin  Advanced melanoma (HLA-A2+)   C Parkinson / B Basu
 MOv18 IgE  IgE antibody/α-FR α-Folate receptor over-expressing gynaecological tumours B Basu
 ONX-0801  α-folate receptor  Platinum resistant ovarian cancer B Basu 
OUTREACH 
MNA-3521
 CEBPα Hepatocellular carcinoma  B Basu 
 PARADIGM 2  PARP Glioblastoma stratified by MGMT status   S Jeffries / R Baird
POSEIDON phase II   PI3K HR+ metastatic breast cancer   R Baird
 STARTRK2  NTRK1/2/3/ROS1/ALK Proven NTRK1/2/3, ROS1 or ALK gene rearrangements   S Pacey
VAPER hTERT Advanced solid tumours R Baird